{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:14:09Z","timestamp":1790198049560,"version":"4.1.0"},"reference-count":66,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high as 90% using the current treatment protocols, the prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at the time of diagnosis is an unmet clinical need. Endothelial activation and stress index (EASIX) and its variant modified EASIX (mEASIX) is a scoring system currently used for the prediction of prognosis in hematologic malignancies. This study aimed to investigate the prognostic value of the mEASIX score in newly diagnosed cHL patients. Methods: Data from 206 patients who underwent positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy for cHL between January 2007 and November 2023 were retrospectively analyzed. The prognostic value of the mEASIX score was evaluated using the receiver operating characteristic (ROC) analysis, Cox regression analysis, and the Kaplan\u2013Meier method, and then compared with standard risk assessment methods. Results: The median age at diagnosis was 33 years, and the rate of patients in the advanced stage was 67%. ROC analysis determined an optimal mEASIX score cut-off of 17.28, categorizing patients into mEASIXhigh (47%) and mEASIXlow (53%) groups. The 5-year progression-free survival (PFS) (60% vs. 84.3%) and overall survival (OS) (79.6% vs. 95.8%) were significantly lower in the mEASIXhigh group (p &lt; 0.001). Additionally, multivariate analysis showed that the independent variables affecting PFS included the nodular sclerosing subtype (HR: 0.4), bone marrow involvement (HR: 2.6), and elevated mEASIX (HR: 3.1). Independent variables, which had an effect on OS included elevated mEASIX (HR:3.8) and higher IPS-3 scores (HR:1.9). Furthermore, a higher mEASIX score (\u226517.28) was identified as an independent variable indicating primary refractory disease (OR: 6.5). Conclusions: mEASIX is a powerful and easy-to-access marker for the detection of primary refractory disease and prognosis in newly diagnosed cHL cases.<\/jats:p>","DOI":"10.3390\/diagnostics15020185","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T13:49:32Z","timestamp":1736862572000},"page":"185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-9830","authenticated-orcid":false,"given":"Faz\u0131l \u00c7a\u011fr\u0131","family":"Hunutlu","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmet","family":"\u00d6ztop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"G\u00fcrsoy","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Ersal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezel","family":"Elg\u00fcn","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-2220","authenticated-orcid":false,"given":"Selin","family":"\u0130ldemir Ekizo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1509-2732","authenticated-orcid":false,"given":"Azim Ali","family":"Ekizo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"\u00d6zkocaman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahir","family":"\u00d6zkalemka\u015f","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer Statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0950-3536(96)80018-7","article-title":"The Epidemiology of Hodgkin\u2019s Disease","volume":"9","author":"Glaser","year":"1996","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin Lymphoma: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular Biology of Hodgkin Lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s Lymphoma When High-Dose Salvage Is Planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clinthera.2016.12.010","article-title":"Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States","volume":"39","author":"Lin","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach with Stage III\/IV Hodgkin Lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group","volume":"96","author":"Josting","year":"2000","journal-title":"Blood."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study","volume":"37","author":"Barrington","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A Prognostic Score for Advanced Hodgkin\u2019s Disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for Advanced Hodgkin Lymphoma in the Modern Era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1111\/bjh.16903","article-title":"Validation of the Simplified International Prognostic Score3 in a Hellenic Cohort of Patients with Advanced-Stage Hodgkin-Lymphoma","volume":"190","author":"Asimakopoulos","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjh.16293","article-title":"Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced-Stage Classic Hodgkin Lymphoma","volume":"189","author":"Hayden","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin\u2019s Lymphoma: A Report from a Joint Italian-Danish Study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2967\/jnumed.120.242594","article-title":"Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?","volume":"61","author":"Mesguich","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-020-01186-6","article-title":"Early Bilirubinemia after Allogeneic Stem Cell Transplantation-an Endothelial Complication","volume":"56","author":"Dai","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in Patients with Acute Graft-versus-Host Disease: A Retrospective Cohort Analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semnephrol.2015.01.010","article-title":"Renal Endothelial Injury and Microvascular Dysfunction in Acute Kidney Injury","volume":"35","author":"Verma","year":"2015","journal-title":"Semin. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-18603-0_2","article-title":"Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions","volume":"865","author":"Karpman","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1378\/chest.06-2233","article-title":"Platelet Count Decline: An Early Prognostic Marker in Critically Ill Patients with Prolonged ICU Stays","volume":"131","author":"Moreau","year":"2007","journal-title":"Chest"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2023.11.016","article-title":"Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation","volume":"30","author":"Pedraza","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3324\/haematol.2019.238790","article-title":"Predicting Sinusoidal Obstruction Syndrome after Allogeneic Stem Cell Transplantation with the EASIX Biomarker Panel","volume":"106","author":"Jiang","year":"2021","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX Predicts Severe Cytokine Release Syndrome and Neurotoxicity after Chimeric Antigen Receptor T Cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zi\u0144czuk, A., Rorat, M., Simon, K., and Jurek, T. (2022). EASIX, Modified EASIX and Simplified EASIX as an Early Predictor for Intensive Care Unit Admission and Mortality in Severe COVID-19 Patients. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071022"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Schult, D., Rasch, S., Schmid, R.M., Lahmer, T., and Mayr, U. (2023). EASIX Is an Accurate and Easily Available Prognostic Score in Critically Ill Patients with Advanced Liver Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072553"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Song, G.Y., Jung, S.H., Kim, K., Kim, S.J., Yoon, S.E., Lee, H.S., Kim, M., Ahn, S.Y., Ahn, J.S., and Yang, D.H. (2020). Endothelial Activation and Stress Index (EASIX) Is a Reliable Predictor for Overall Survival in Patients with Multiple Myeloma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07317-y"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41408-019-0247-z","article-title":"EASIX for Prediction of Survival in Lower-Risk Myelodysplastic Syndromes","volume":"9","author":"Merz","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Park, S., Go, S., and Lee, G.W. (2022). The Endothelial Activation and Stress Index (EASIX) Score Is an Independent Prognostic Factor in Patients with Diffuse Large B-Cell Lymphoma. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09915-4"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s00277-023-05437-6","article-title":"Endothelial Activation and Stress Index as a Prognostic Factor of Diffuse Large B-Cell Lymphoma: The Report from the Nationwide Multi-Center Thai Lymphoma Study Group","volume":"102","author":"Thanhakun","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a Committee Convened to Discuss the Evaluation and Staging of Patients with Hodgkin\u2019s Disease: Cotswolds Meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Honor\u00e9, B., Andersen, M.D., Wilken, D., Kamper, P., D\u2019amore, F., Hamilton-Dutoit, S., and Ludvigsen, M. (2022). Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers, 14.","DOI":"10.3390\/cancers14010247"},{"key":"ref_35","first-page":"2576","article-title":"Concurrent Pembrolizumab with AVD for Untreated Classic Hodgkin Lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the Efficacy and Tolerability of PET-Guided BrECADD versus EBEACOPP in Advanced-Stage, Classical Hodgkin Lymphoma (HD21): A Randomised, Multicentre, Parallel, Open-Label, Phase 3 Trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in Advanced-Stage Hodgkin\u2019s Lymphoma: Altered Utility in the Modern Era","volume":"30","author":"Moccia","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/10428194.2014.917636","article-title":"CD68-Positive Tumor-Associated Macrophages Predict Unfavorable Treatment Outcomes in Classical Hodgkin Lymphoma in Correlation with Interim Fluorodeoxyglucose-Positron Emission Tomography Assessment","volume":"56","author":"Touati","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106586","DOI":"10.1016\/j.leukres.2021.106586","article-title":"Easier and More Explanatory Indices by Integrating Leukocyte Lymphocyte Ratio (LLR) and Prognostic Nutritional Index (PNI) to IPS Systems in Cases with Classical Hodgkin Lymphoma","volume":"107","author":"Paydas","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bertuzzi, C., Sabattini, E., and Agostinelli, C. (2021). Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13143634"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.14245","article-title":"Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation","volume":"175","author":"Shah","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1182\/bloodadvances.2024013743","article-title":"Evaluation of Prognostic Factors in Patients with High-Risk Classical Hodgkin Lymphoma Undergoing Autologous Transplantation","volume":"8","author":"Epperla","year":"2024","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-017-16955-5","article-title":"The Role of the Systemic Inflammatory Response in Predicting Outcomes in Patients with Operable Cancer: Systematic Review and Meta-Analysis","volume":"7","author":"Dolan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.21873\/anticanres.13602","article-title":"Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer","volume":"39","author":"Matsuda","year":"2019","journal-title":"Anticancer. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline Serum TARC Levels Predict Therapy Outcome in Patients with Hodgkin Lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101514","DOI":"10.1016\/j.beha.2023.101514","article-title":"Hodgkin Lymphoma: A Disease Shaped by the Tumor Micro- and Macroenvironment","volume":"36","author":"Masel","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental Interactions in Classical Hodgkin Lymphoma and Their Role in Promoting Tumor Growth, Immune Escape and Drug Resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical Significance of Macrophage Heterogeneity in Human Malignant Tumors","volume":"105","author":"Komohara","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Koh, Y.W., Park, C.S., Yoon, D.H., Suh, C., and Huh, J. (2014). CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087066"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/sj.leu.2403992","article-title":"Angiogenesis and Mast Cells in Hodgkin Lymphoma","volume":"19","author":"Glimelius","year":"2005","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1365-2141.2002.03768.x","article-title":"Mast Cell Infiltration Correlates with Poor Prognosis in Hodgkin\u2019s Lymphoma","volume":"119","author":"Molin","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02893504","article-title":"Retrospective Analysis of the Prognostic Role of Tissue Eosinophil and Mast Cells in Hodgkin\u2019s Lymphoma","volume":"13","author":"Keresztes","year":"2007","journal-title":"Pathol. Oncol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MBC.0000000000001031","article-title":"Assessment of Endothelial Progenitor Cells, VEGF-A and SDF-1\u03b1 in Hodgkin\u2019s Lymphoma","volume":"32","author":"Filipiak","year":"2021","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2006.08.1331","article-title":"Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients with Classical Hodgkin\u2019s Lymphoma: A Study from the Groupe d\u2019Etude Des Lymphomes de l\u2019Adulte","volume":"25","author":"Casasnovas","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/10428194.2021.2010054","article-title":"Serum Ferritin Levels in Previously Untreated Classical Hodgkin Lymphoma: Correlations and Prognostic Significance","volume":"63","author":"Karakatsanis","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1034\/j.1600-0609.2001.00561.x","article-title":"Prognostic Factors in Advanced Stage Hodgkin\u2019s Lymphoma: The Significance of the Number of Involved Anatomic Sites","volume":"67","author":"Vassilakopoulos","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Piperidou, A., Zografos, E., Vassilakopoulos, T.J., Angelopoulou, M.K., Hillas, G., Pappis, V., Boutsikas, G., Dimou, M., Petevi, K., and Kanellopoulos, A. (2022). Serum Procalcitonin Levels in Newly Diagnosed Hodgkin Lymphoma: Correlation with Other Inflammatory Biomarkers. Medicina, 58.","DOI":"10.3390\/medicina58101331"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2217\/bmm-2019-0303","article-title":"Systemic Immune-Inflammation Index Predicting Survival Outcome in Patients with Classical Hodgkin Lymphoma","volume":"13","author":"Mirili","year":"2019","journal-title":"Biomark. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/ajco.13770","article-title":"A New Prognostic Model Including Platelet\/Lymphocyte Ratio and International Prognostic Score 3 for Freedom from Progression in Patients with Previously Untreated Advanced Classical Hodgkin Lymphoma","volume":"18","author":"Tao","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41409-023-01922-8","article-title":"EASIX Score Predicts Inferior Survival after Allogeneic Hematopoietic Cell Transplantation","volume":"58","author":"Flynn","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Nie, G., Sun, L., Zhang, C., Yuan, Y., Mao, H., Wang, Z., Li, J., Duan, S., Xing, C., and Zhang, B. (2022). Clinicopathological Features and Individualized Treatment of Kidney Involvement in B-Cell Lymphoproliferative Disorder. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.903315"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:50Z","timestamp":1759919330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["diagnostics15020185"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15020185","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}